echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Natural Products News > Progress in immunochemical biology of natural products

    Progress in immunochemical biology of natural products

    • Last Update: 2019-06-23
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Natural killer (NK) cells are an important immune cell group to monitor the early development of tumor The interaction between the activated receptor NKG2D (natural killer group 2 member d) on the cell surface and the NKG2D ligands on the cell surface plays an important role in the process of NK cells carrying out tumor immune surveillance The down-regulation or deletion of NKG2D ligand expression will lead to the weakening of tumor cell immunogenicity, thus escaping the recognition and killing effect of NK cells Therefore, activating the expression of NKG2D ligand on the surface of tumor cell membrane is an effective strategy to enhance the tumor immune monitoring and clearance of NK cells Li Yan research group, natural product pharmacology and new drug creation team, State Key Laboratory of Phytochemistry and sustainable utilization of Western plant resources, Kunming Institute of Botany, Chinese Academy of Sciences, and Puno baimadanza research group, important group phytochemistry and function research team, have obtained a series of NKG2D ligands on the surface of tumor cell membrane through extensive and close cooperation The enantiomeric kaurane diterpenoids of In-depth chemical biology and molecular biology research, parvifoline AA (PAA) leads to reactive oxygen species (ROS) in cells by targeting peroxidase I and II (peroxiredoxins I / II, prxs-i / II) With the increase of specific, ROS) and activation of ERK, the expression of NKG2D ligand on the surface of hepatoma cell membrane was significantly increased, and then the immune activity of NK cells was activated, which promoted the immune killing and clearance of NK cells to hepatoma cells in vivo and in vitro The results not only revealed the important regulatory role of prx-i / II in NK cell-mediated liver tumor immunity, but also suggested that PAA, as a sensitizer of immunotherapy for NK cell hepatocarcinoma, has important drug development potential and application prospect This study provides potential important molecular targets and drug molecules for tumor immunotherapy based on NK cells The research results were published online in cell chemical biology, a subsidiary of cell journal, under the title of parvifoline AA promotions sustainability of Hepatecarcinoma to natural killer cell mediated circulation by targeting peroxiredoxin Zhu Huifang and Wang Bin are the co authors of the article, Li Yan and Puno baimadanzheng are the co authors of the article The research was supported by the National Natural Science Foundation of China, the Characteristic Research Institute of Kunming Institute of Botany, the 100 person plan of Chinese Academy of Sciences and the high-end scientific and Technological Talents Project of Yunnan Province.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.